Fig. 1 | Genetics in Medicine

Fig. 1

From: Frequency and clinical outcomes of CYP2C19 genotype-guided escalation and de-escalation of antiplatelet therapy in a real-world clinical setting

Fig. 1

P2Y12 inhibitor maintenance therapy selection and switching by CYP2C19 status. a Maintenance therapy distribution by switch status in genotyped patients (n = 1063). Left panel: initiated and continued on clopidogrel or alternative therapy (i.e., not switched). *Two switched from prasugrel to ticagrelor; one from ticagrelor to prasugrel. Right panel: switched to alternative therapy (escalation) or to clopidogrel (de-escalation). b Distribution of escalation and de-escalation by CYP2C19 phenotype. IM intermediate metabolizer, NM normal metabolizer, PM poor metabolizer, RM rapid metabolizer, UM ultrarapid metabolizer.

Back to article page